The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice

Journal of Neurochemistry
Melinda WestKenneth Hensley

Abstract

Familial forms of amyotrophic lateral sclerosis (ALS) can be caused by mutations in copper, zinc-superoxide dismutase (SOD1). Mice expressing SOD1 mutants demonstrate a robust neuroinflammatory reaction characterized, in part, by up-regulation of tumor necrosis factor alpha (TNFalpha) and its primary receptor TNF-RI. In an effort to identify small molecule inhibitors of neuroinflammation useful in treatment of ALS, a microglial culture system was established to identify TNFalpha antagonists. Walker EOC-20 microglia cells were stimulated with recombinant TNFalpha, with or without inhibitors, and the cell response was indexed by NO2- output. Three hundred and fifty-five rationally selected compounds were included in this bioassay. The arachidonic acid 5-lipoxygenase (5LOX) and tyrosine kinase inhibitor nordihydroguaiaretic acid (NDGA), a natural dicatechol, was one of the most potent non-cytotoxic antagonists tested (IC50 8 +/- 3 microm). Investigation of the G93A-SOD1 mouse model for ALS revealed increased message and protein levels of 5LOX at 120 days of age. Oral NDGA (2500 p.p.m.) significantly extended lifespan and slowed motor dysfunction in this mouse, when administration was begun relatively late in life (90 days). NDGA e...Continue Reading

References

Jan 1, 1979·Kidney International·A P Evan, K D Gardner
Nov 17, 1994·Annals of the New York Academy of Sciences·C A ColtonD L Gilbert
Apr 16, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T UzH Manev
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·R T MatthewsM F Beal
Jul 24, 1998·Hormone Research·H J Aanstoot
Dec 16, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·D S GaryM P Mattson
Jul 1, 1999·Journal of Neurochemistry·K Kanemaru, T Tajika
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·O WerzO Rådmark
Jul 6, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H ManevT Qu
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·Y ShishidoT Yokokura
Nov 1, 2001·Brain Research. Molecular Brain Research·J L Elliott
Jan 5, 2002·Neurobiology of Aging·P L McGeer, E G McGeer
Jun 13, 2002·Neuroreport·Ludo Van Den BoschWim Robberecht
Jun 29, 2002·Cellular and Molecular Life Sciences : CMLS·J Z Haeggström, A Wetterholm
Jul 20, 2002·Molecular Pharmacology·Timothy D Bigby
Aug 14, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Joseph C Shanahan, William St Clair
Sep 25, 2002·Neurobiology of Disease·Jasna KrizJean-Pierre Julien
Nov 29, 2002·Nature Medicine·John M Hallenbeck
Feb 15, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·P N PomplG M Pasinetti
Jan 1, 1951·Advances in Food Research·A J LEHMANG WOODARD

❮ Previous
Next ❯

Citations

Aug 30, 2011·Apoptosis : an International Journal on Programmed Cell Death·Ujwal Mukund MahajanKulbhushan Tikoo
Oct 13, 2006·Antioxidants & Redox Signaling·Mark P Mattson
Jun 2, 2012·Journal of Neuroinflammation·Branden StansleyKenneth Hensley
Nov 18, 2009·Molecular Neurodegeneration·Tamy C Frank-CannonMalú G Tansey
Aug 6, 2008·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Milos D IkonomovicSteven T Dekosky
Jun 21, 2011·PloS One·Jesse A SolomonMazen J Hamadeh
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Stefano ZoccolellaPaolo Lamberti
Jul 26, 2012·Neurology Research International·Kalina Venkova-HristovaKenneth Hensley
Jul 9, 2010·Progress in Neurobiology·Elisabetta Polazzi, Barbara Monti
Oct 17, 2009·Neurobiology of Disease·Dimitra PapadimitriouDiane B Re
Feb 16, 2007·Neurobiology of Disease·Michael Benatar
Jul 24, 2015·Journal of Cellular Physiology·Stewart Siyan CaoLynn Shi
May 17, 2008·CNS Neuroscience & Therapeutics·Jun-Qing YangBai-Cheng He
Jun 21, 2007·Aging Cell·Richard A MillerRandy Strong
Nov 26, 2015·Journal of Neuroinflammation·Carolin DahlkeCarsten Theiss
Sep 11, 2014·Drug Discovery Today·Yongjin ZhuXin Wang
Nov 22, 2007·Expert Opinion on Therapeutic Targets·Juan C CoronaRicardo Tapia
Oct 4, 2006·Neuron·Séverine BoilléeDon W Cleveland
May 15, 2009·Free Radical Biology & Medicine·Siân C BarberPamela J Shaw
May 28, 2016·Journal of Neuroinflammation·Inna Rabinovich-NikitinBeka Solomon
Feb 25, 2014·Journal of Biomolecular Screening·S Joshua SwamidassPankaj Agarwal
Feb 8, 2005·Biochemical and Biophysical Research Communications·Sae-Bom JeonEun-Hye Joe
Jun 1, 2007·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Andrew P Smith, Nancy M Lee
Apr 15, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Anna LeonovVladimir I Titorenko
Aug 18, 2010·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kenneth HensleyAlexandar Christov

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.